Literature DB >> 21847533

Molecular mechanisms of liver metastasis.

Kenji Kawada1, Suguru Hasegawa, Teppei Murakami, Yoshiro Itatani, Hisahiro Hosogi, Masahiro Sonoshita, Takanori Kitamura, Teruaki Fujishita, Masayoshi Iwamoto, Takuya Matsumoto, Ryo Matsusue, Koya Hida, Gaku Akiyama, Kae Okoshi, Masahiro Yamada, Junichiro Kawamura, Makoto Mark Taketo, Yoshiharu Sakai.   

Abstract

Colorectal cancer is the second most common cancer, and is the third leading cause of cancer-related death in Japan. The majority of these deaths is attributable to liver metastasis. Recent studies have provided increasing evidence that the chemokine-chemokine receptor system is a potential mechanism of tumor metastasis via multiple complementary actions: (a) by promoting cancer cell migration, invasion, survival and angiogenesis; and (b) by recruiting distal stromal cells (i.e., myeloid bone marrow-derived cells) to indirectly facilitate tumor invasion and metastasis. Here, we discuss recent preclinical and clinical data supporting the view that chemokine pathways are potential therapeutic targets for liver metastasis of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21847533     DOI: 10.1007/s10147-011-0307-2

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  85 in total

1.  Discovery of a novel series of CXCR3 antagonists.

Authors:  Stefano Crosignani; Marc Missotten; Christophe Cleva; Ruggero Dondi; Yann Ratinaud; Yves Humbert; Ashis Baran Mandal; Agnès Bombrun; Christine Power; André Chollet; Amanda Proudfoot
Journal:  Bioorg Med Chem Lett       Date:  2010-04-28       Impact factor: 2.823

Review 2.  Chemokines and their role in tumor growth and metastasis.

Authors:  J M Wang; X Deng; W Gong; S Su
Journal:  J Immunol Methods       Date:  1998-11-01       Impact factor: 2.303

3.  Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.

Authors:  Joseph Kim; Hiroya Takeuchi; Stella T Lam; Roderick R Turner; He-Jing Wang; Christine Kuo; Leland Foshag; Anton J Bilchik; Dave S B Hoon
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

4.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

5.  C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells.

Authors:  Sachie Hiratsuka; Dan G Duda; Yuhui Huang; Shom Goel; Tatsuki Sugiyama; Takashi Nagasawa; Dai Fukumura; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

Review 6.  Significance and mechanism of lymph node metastasis in cancer progression.

Authors:  Kenji Kawada; Makoto M Taketo
Journal:  Cancer Res       Date:  2011-01-06       Impact factor: 12.701

Review 7.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

8.  Novel CXCR3 antagonists with a piperazinyl-piperidine core.

Authors:  Brian F McGuinness; Carolyn DiIanni Carroll; Lisa Guise Zawacki; Guizhen Dong; Cangming Yang; Doug W Hobbs; Biji Jacob-Samuel; James W Hall; Chung-Her Jenh; Joseph A Kozlowski; Gopinadhan N Anilkumar; Stuart B Rosenblum
Journal:  Bioorg Med Chem Lett       Date:  2009-07-09       Impact factor: 2.823

9.  Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis.

Authors:  T Ueda; E Shimada; T Urakawa
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

10.  Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism.

Authors:  B Cambien; B F Karimdjee; P Richard-Fiardo; H Bziouech; R Barthel; M A Millet; V Martini; D Birnbaum; J Y Scoazec; J Abello; T Al Saati; M G Johnson; T J Sullivan; J C Medina; T L Collins; A Schmid-Alliana; H Schmid-Antomarchi
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

View more
  9 in total

1.  Activation of ETA Receptor by Endothelin-1 Induces Hepatocellular Carcinoma Cell Migration and Invasion via ERK1/2 and AKT Signaling Pathways.

Authors:  Ning Cong; Zhongmin Li; Wenbo Shao; Jinpeng Li; Shui Yu
Journal:  J Membr Biol       Date:  2015-10-26       Impact factor: 1.843

Review 2.  Impact of proteolytic enzymes in colorectal cancer development and progression.

Authors:  László Herszényi; Loránd Barabás; István Hritz; Gábor István; Zsolt Tulassay
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

3.  Impact of Synchronous Liver Resection on the Perioperative Outcomes of Patients Undergoing CRS-HIPEC.

Authors:  Jordan M Cloyd; Sherif Abdel-Misih; John Hays; Mary E Dillhoff; Timothy M Pawlik; Carl Schmidt
Journal:  J Gastrointest Surg       Date:  2018-04-30       Impact factor: 3.452

4.  CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer.

Authors:  Ming Bai; Xia Chen; Y I Ba
Journal:  Mol Clin Oncol       Date:  2015-10-30

5.  Extracellular HSP70/HSP70-PCs regulate hepatocarcinoma cell migration and invasion via RhoA.

Authors:  Zhe Yi; Yan Li; Dan Liu; Jingang Liu; Hangyu Li
Journal:  Oncol Lett       Date:  2016-12-30       Impact factor: 2.967

6.  The Role Of Hepatic Stellate Cells In Promoting Liver Metastasis Of Colorectal Carcinoma.

Authors:  Wen-Hai Huang; Min-Wei Zhou; Yan-Feng Zhu; Jian-Bin Xiang; Zhen-Yang Li; Zi-Hao Wang; Yi-Ming Zhou; Yi Yang; Zong-You Chen; Xiao-Dong Gu
Journal:  Onco Targets Ther       Date:  2019-09-16       Impact factor: 4.147

7.  Patterns of recurrence after liver transplantation for nonresectable liver metastases from colorectal cancer.

Authors:  Morten Hagness; Aksel Foss; Tor Skatvedt Egge; Svein Dueland
Journal:  Ann Surg Oncol       Date:  2013-12-27       Impact factor: 5.344

8.  Serum CA19-9 as a marker of circulating tumor cells in first reflux blood of colorectal cancer patients.

Authors:  Jia-Xing Zhao; Zhong-Guo Zhang; Li-Ren Liu; Xiao-Yu Yang; Fang Liu
Journal:  Oncotarget       Date:  2017-07-01

9.  Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD44s and the ERK1/2 pathway.

Authors:  Helei Hou; Chao Ge; Hefen Sun; Hong Li; Jinjun Li; Hua Tian
Journal:  Cancer Sci       Date:  2018-02-26       Impact factor: 6.716

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.